Protalix BioTherapeutics’ (PLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at $0.16 EPS and […]

Leave a Reply

Your email address will not be published.

Previous post New York Community Bancorp (NYSE:NYCB) Downgraded by Wedbush
Next post Wells Fargo & Company Increases RBC Bearings (NYSE:RBC) Price Target to $240.00